A proposed class action was recently filed in New Jersey federal court on behalf of direct purchasers against Johnson & Johnson unit Janssen Biotech and BTG International, alleging the companies filed “sham” patent litigation to block generic competition for the blockbuster prostate cancer drug Zytiga.
The lawsuit states that Janssen obtained a patent on the compound in Zytiga in 1997, launched the drug in 2011, and that the initial patent expired in 2016. The suit alleges that in order to maintain the drug’s sales of over $1 billion a year, Janssen sought and obtained a second patent in 2014. Despite initially rejecting Janssen’s second patent application, finding that the formulation was too obvious to patent, the United States Patent and Trademark Office eventually agreed with Janssen’s argument that Zytiga’s “commercial success” showed that combining abiraterone with a steroid was not obvious. But Janssen allegedly concealed the true reason for Zytiga’s success: BTG’s earlier, separate patent on abiraterone itself (which Janssen had a license on) blocked other companies from making or selling a competing abiraterone product. Plaintiffs allege that Janssen and BTG asserted that second patent in meritless infringement litigation against would-be makers of generic Zytiga. Plaintiffs allege that this conduct delayed generic competition, and that absent Janssen’s sham suits, generic versions of Zytiga would have been available in 2016.
The case is KPH Healthcare Servs. Inc. v. Janssen Biotech Inc., No. 20-cv-5901 (D.N.J.). A similar lawsuit was filed about a year ago on behalf of a proposed class of end-payors that purchased Zytiga indirectly from defendants.
About Faruqi & Faruqi, LLP
Faruqi & Faruqi, LLP focuses on complex civil litigation, including securities, antitrust, wage and hour, personal injury and consumer class actions as well as shareholder derivative and merger and transactional litigation. The firm is headquartered in New York, and maintains offices in California, Delaware, Georgia and Pennsylvania.
Since its founding in 1995, Faruqi & Faruqi, LLP has served as lead or co-lead counsel in numerous high-profile cases which ultimately provided significant recoveries to investors, direct purchasers, consumers and employees.
To schedule a free consultation with our attorneys and to learn more about your legal rights, call our offices today at (877) 247-4292 or (212) 983-9330.
About Kristyn Fields
Kristyn Fields' practice is focused on antitrust litigation. Kristyn is a Senior Associate in the firm's New York office.Prior to joining F&F, Kristyn interned for the Honorable Martin Marcus, New York Supreme Court, Bronx County. As well, Kristyn participated in the Brooklyn Law Incubator & Policy Clinic providing pro bono counsel to emerging start-up companies. While at Brooklyn Law School, Kristyn served as an Executive Articles Editor of the Brooklyn Journal of Corporate, Financial & Commercial Law. Also, Kristyn was a member of the Moot Court Honor Society.Kristyn earned her J.D. from Brooklyn Law School (2016). Kristyn earned her undergraduate degree from Boston College (B.A., Political Science, 2013).Kristyn is licensed to practice law in New York.